Figure 6.

IL-10R is highly upregulated by PD-1⁺ CD8⁺ TILs. A and B, Dot plots from one representative patient (A) and summary data (B) showing ex vivo IL-10R expression by NY-ESO-1 tet^- CD8⁺ T cells from PBMCs of healthy donors (n=9) and by CD8⁺ TILs from melanoma patients (n=9). C and D, Dot plots from one representative patient (C) and summary data for all nine patients with advanced melanoma (D) showing ex vivo IL-10R expression by PD-1^high, PD-1^int and PD-1^low subsets of CD8⁺ TILs. E, Flow cytometry analysis from one melanoma patient showing the percentages of CFSE^lo CD8⁺ TILs among total CD8⁺ TILs. CFSE-labeled CD8⁺ TILs were incubated with anti-CD3-pulsed non-T cell fraction of one melanoma tumor single cell suspension in the presence of anti-IL-10R and/or anti-PD-1 or IgG control antibodies before the evaluation of the CD8⁺ T cells proliferation by flow cytometry. * P < 0.05 and ** P < 0.01. Horizontal bars depict the mean percentage or MFI of IL-10R expression by NY-ESO-1 tet^- CD8⁺ T cells or CD8⁺ TILs. Data shown are representative of two independent experiments performed in duplicate.